SCHEMBL2006948

SCHEMBL2006948

COC(=O)C(=O)N1CCC[C@@]1(C)C(=O)O

nearest known ligand 0.34

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
USP2 O75604 1/20 0.31
FFAR3 O14843 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7874674 0.95 FKBP1A (0.31)
SCHEMBL6429489 0.95 FKBP1A (0.31)
SCHEMBL7245081 0.89 FFAR3 (0.32) FFAR3
SCHEMBL2683916 0.82 USP2 (0.39) USP2
Hydrochloric Acid SCHEMBL10884122 0.81 USP2 (0.38) USP2
SCHEMBL12193293 0.80 CNR2 (0.33) USP2
SCHEMBL7324549 0.80 FFAR3 (0.33) FFAR3
SCHEMBL8669400 0.78 FKBP1A (0.33) USP2
SCHEMBL3133271 0.77 FFAR3 (0.37) FFAR3
SCHEMBL15125244 0.77 FFAR3 (0.37) FFAR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7960570-B2 Small molecule inhibitors of rotamase enzyme activity GLIAMED, INC. (US) 2011-06-14 US claimed
US-20100145071-A1 SMALL MOLECULE INHIBITORS OF ROTAMASE ENZYME ACTIVITY GLIAMED, INC. (US) 2010-06-10 US claimed
EP-1433781-B1 Pyrrolidine carboxylic acid derivatives MGI GP INC (US) 2010-02-24 EP claimed
EP-1433781-A1 Pyrrolidine carboxylic acid derivatives GPI NIL Holdings, Inc. (US) 2004-06-30 EP claimed
US-20110218343-A1 SMALL MOLECULE INHIBITORS OF ROTAMASE ENZYME ACTIVITY GLIAMED, INC. (US) 2011-09-08 US disclosed
US-7960570-B2 Small molecule inhibitors of rotamase enzyme activity GLIAMED, INC. (US) 2011-06-14 US disclosed
EP-1900726-A1 Heterocyclic thioesters MGI GP, Inc. (US) 2008-03-19 EP disclosed
EP-1626043-A1 Heterocyclic thioesters MGI GP, Inc. (US) 2006-02-15 EP disclosed
US-6984639-B2 Heterocyclic ketone and thioester compounds and uses GPI NIL HOLDINGS, INC. (US) 2006-01-10 US disclosed
US-20050148637-A1 Heterocyclic ketone and thioester compounds and uses GPI NIL HOLDINGS, INC. 2005-07-07 US disclosed
US-20050059693-A1 Heterocyclic thioester and ketone hair growth compositions and uses GPI NIL HOLDINGS, INC. 2005-03-17 US disclosed
US-20040186098-A1 Method for preventing and treating hearing loss using sensorineurotrophic compounds AMGEN INC. 2004-09-23 US disclosed
EP-1104299-A2 N-LINKED UREA OR CARBAMATE OF HETEROCYCLIC THIOESTERS FOR VISION AND MEMORY DISORDERS GPI NIL Holdings, Inc. (US) 2001-06-06 EP disclosed
US-6218424-B1 FOR EFFECTING NEURONAL ACTIVITIES IN ANIMALS, INCLUDING TREATING NEUROLOGICAL DISORDERS GPI NIL HOLDINGS, INC. 2001-04-17 US disclosed
EP-1082095-A1 N-OXIDE OF HETEROCYCLIC ESTER, AMIDE, THIOESTER OR KETONE HAIR GROWTH COMPOSITIONS AND USES GPI NIL Holdings, Inc. (US) 2001-03-14 EP disclosed
WO-2000009484-A1 PIPECOLIC ACID DERIVATIVES AND THEIR USE FOR VISION AND MEMORY DISORDERS GPI NIL HOLDINGS, INC. (US) 2000-02-24 WO disclosed
WO-2000009108-A2 COMPOSITIONS AND USES FOR VISION AND MEMORY DISORDERS GPI NIL HOLDINGS, INC. (US) 2000-02-24 WO disclosed
WO-2000009110-A2 N-LINKED UREA OR CARBAMATE OF HETEROCYCLIC THIOESTERS FOR VISION AND MEMORY DISORDERS GPI NIL HOLDINGS INC. (US) 2000-02-24 WO disclosed
WO-1999062486-A1 N-OXIDE OF HETEROCYCLIC ESTER, AMIDE, THIOESTER, OR KETONE HAIR GROWTH COMPOSITIONS AND USES GPI NIL HOLDINGS INC. (US) 1999-12-09 WO disclosed
US-5990131-A OF GIVEN FORMULA WHICH HAVE A HIGH AFFINITY FOR FKBPS (FK506 BINDING PROTEINS, A CLASS OF IMMUNOPHILINS) ARE POTENT ROTAMASE INHIBITORS AND EXHIBIT EXCELLENT NEUROTROPHIC EFFECTS; NO IMMUNOSUPPRESSIVE ACTIVITY GPI NIL HOLDINGS INC. (US) 1999-11-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040186098-A1 Method for preventing and treating hearing loss using sensorineurotrophic compounds GAP43, CHAT, MYOC USP2 2966/4885FFAR3 3311/4885
US-20100145071-A1 SMALL MOLECULE INHIBITORS OF ROTAMASE ENZYME ACTIVITY FKBP8, FKBP1A, FKBP2 USP2 1111/4885FFAR3 4691/4885
US-20050059693-A1 Heterocyclic thioester and ketone hair growth compositions and uses ACOT7, HSD17B7, ZDHHC7 USP2 1545/4885FFAR3 497/4885
US-20050148637-A1 Heterocyclic ketone and thioester compounds and uses BDNF, NTRK2, NTRK1 USP2 2031/4885FFAR3 195/4885
US-20110218343-A1 SMALL MOLECULE INHIBITORS OF ROTAMASE ENZYME ACTIVITY FKBP8, FKBP1A, FKBP2 USP2 1111/4885FFAR3 4691/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.